X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CIPLA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CIPLA STERLING BIOTECH/
CIPLA
 
P/E (TTM) x -0.4 33.7 - View Chart
P/BV x 0.0 2.9 0.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 STERLING BIOTECH   CIPLA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CIPLA
Mar-18
STERLING BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs11663 1.6%   
Low Rs3479 0.7%   
Sales per share (Unadj.) Rs26.8189.0 14.2%  
Earnings per share (Unadj.) Rs-15.017.6 -85.0%  
Cash flow per share (Unadj.) Rs-5.534.0 -16.1%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs54.9176.7 31.1%  
Shares outstanding (eoy) m267.87805.12 33.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 8.6%   
Avg P/E ratio x-0.532.5 -1.4%  
P/CF ratio (eoy) x-1.316.8 -7.6%  
Price / Book Value ratio x0.13.2 3.9%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m1,862459,724 0.4%   
No. of employees `0001.423.6 5.7%   
Total wages/salary Rs m54726,901 2.0%   
Avg. sales/employee Rs Th5,303.36,446.1 82.3%   
Avg. wages/employee Rs Th403.81,139.4 35.4%   
Avg. net profit/employee Rs Th-2,959.0600.0 -493.2%   
INCOME DATA
Net Sales Rs m7,181152,193 4.7%  
Other income Rs m433,577 1.2%   
Total revenues Rs m7,223155,769 4.6%   
Gross profit Rs m94728,264 3.4%  
Depreciation Rs m2,54313,228 19.2%   
Interest Rs m4,3771,142 383.2%   
Profit before tax Rs m-5,93117,470 -33.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m-1,9242,501 -76.9%   
Profit after tax Rs m-4,00714,166 -28.3%  
Gross profit margin %13.218.6 71.0%  
Effective tax rate %32.414.3 226.6%   
Net profit margin %-55.89.3 -599.5%  
BALANCE SHEET DATA
Current assets Rs m14,335108,141 13.3%   
Current liabilities Rs m49,80938,322 130.0%   
Net working cap to sales %-494.045.9 -1,076.9%  
Current ratio x0.32.8 10.2%  
Inventory Days Days40397 415.8%  
Debtors Days Days17174 229.3%  
Net fixed assets Rs m55,432109,411 50.7%   
Share capital Rs m2681,610 16.6%   
"Free" reserves Rs m13,935140,682 9.9%   
Net worth Rs m14,701142,292 10.3%   
Long term debt Rs m9,47836,621 25.9%   
Total assets Rs m73,988228,606 32.4%  
Interest coverage x-0.416.3 -2.2%   
Debt to equity ratio x0.60.3 250.5%  
Sales to assets ratio x0.10.7 14.6%   
Return on assets %0.56.7 7.5%  
Return on equity %-27.310.0 -273.7%  
Return on capital %-6.410.0 -64.6%  
Exports to sales %25.932.8 79.0%   
Imports to sales %0.20-   
Exports (fob) Rs m1,86049,883 3.7%   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86051,691 3.6%   
Fx outflow Rs m2521,033 0.1%   
Net fx Rs m1,83530,658 6.0%   
CASH FLOW
From Operations Rs m1,71914,628 11.7%  
From Investments Rs m-3,148-8,540 36.9%  
From Financial Activity Rs m1,426-3,855 -37.0%  
Net Cashflow Rs m-32,431 -0.1%  

Share Holding

Indian Promoters % 33.9 16.0 211.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 9.9 23.7 41.8%  
ADR/GDR % 16.9 1.1 1,536.4%  
Free float % 39.3 26.2 150.0%  
Shareholders   21,482 161,166 13.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   AUROBINDO PHARMA  MERCK LTD  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - ASTRAZENECA PHARMA COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS